By the Peptide Insider Research Desk · 12 min read
The incretin receptor agonist class — spanning single-, dual- and triple-receptor designs built on the glucagon-like peptide-1 (GLP-1) backbone — has become one of the most intensively studied peptide families in metabolic research. This review examines the structural lineage from the native GLP-1(7-36) fragment through engineered analogs such as semaglutide (single GLP-1R), tirzepatide (dual GIP/GLP-1R), retatrutide (triple GIP/GLP-1R/GCGR) and the companion amylin analog cagrilintide (AM833), situating each within the peer-reviewed preclinical and clinical literature and mapping the vendor catalogue vocabulary — including tokens such as peptide glp-1, glp 1sg, glp 1t 10mg, short chain aminos glp 1 and solution peptides semaglutide — to verified chemical identities.
All compounds discussed below are presented strictly for research reference; not for human or veterinary use.
Native GLP-1: The Incretin Substrate
Glucagon-like peptide-1 is a 30-amino-acid incretin hormone (GLP-1(7-36)NH₂) produced by post-translational cleavage of proglucagon in intestinal L-cells. Upon nutrient ingestion, GLP-1 binds the GLP-1 receptor (GLP-1R), a class B G protein-coupled receptor expressed on pancreatic beta cells, hypothalamic neurons and vagal afferents, triggering cAMP-dependent insulin exocytosis and suppressing glucagon secretion [1]. The native peptide is rapidly inactivated by dipeptidyl peptidase-4 (DPP-4), which cleaves the His7-Ala8 bond, yielding a circulating half-life of approximately two minutes [1][2]. This extreme lability drove four decades of analog engineering aimed at DPP-4 resistance, albumin binding and receptor-selectivity tuning.
The discovery of exendin-4 — a 39-amino-acid peptide isolated from the venom of Heloderma suspectum (the Gila monster) — provided the first proof that a GLP-1R agonist could resist DPP-4 cleavage while retaining full receptor activation [3]. Exendin-4 shares only ~53% sequence identity with human GLP-1(7-36) but binds GLP-1R with equivalent affinity, demonstrating that the receptor tolerates substantial backbone variation outside the N-terminal activation domain.
Semaglutide: Single GLP-1R Agonist with Fatty-Diacid Acylation
Semaglutide (CAS 910463-68-2) is a 31-amino-acid GLP-1 analog incorporating two key modifications relative to the native sequence: an Aib (α-aminoisobutyric acid) substitution at position 8 that sterically shields the DPP-4 cleavage site, and a Lys26-linked C18 fatty diacid (octadecanedioyl) spacer that enables non-covalent albumin binding, extending the elimination half-life to approximately 165 hours in preclinical pharmacokinetic models [4][5]. This design retains ~97% GLP-1 sequence homology while providing once-weekly dosing kinetics in clinical trial settings.
In preclinical rodent models, semaglutide reduced food intake and body weight through both peripheral (delayed gastric emptying, vagal-afferent signalling) and central (hypothalamic POMC/CART neuron activation) mechanisms [5]. The STEP clinical-trial programme subsequently documented mean body-weight reductions of 14.9% at 68 weeks relative to placebo [4]. Cardiovascular-outcome data from the SELECT trial further reported a 20% reduction in major adverse cardiovascular events in research subjects with established atherosclerotic disease [6].
The catalogue tokens glp 1sg, glp 1sg 10mg and glp 1sg peptide found in vendor listings map to semaglutide reference standards at specified fill masses. Similarly, solution peptides semaglutide, solution peptides glp 1 and solution peptides glp-1 denote semaglutide inventory entries from specific research-compound suppliers. The token soma glp1 appears to be an informal abbreviation. Researchers should verify compound identity by CAS number (910463-68-2) or certificate of analysis before use in any assay.
Tirzepatide: Dual GIP/GLP-1R Agonist (Twincretin)
Tirzepatide (CAS 2023788-19-2) is a 39-amino-acid unimolecular peptide that simultaneously activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and GLP-1R [9]. Structurally, the peptide backbone derives from the human GIP(1-42) sequence with amino-acid substitutions engineered to introduce GLP-1R cross-reactivity; a C20 fatty diacid (eicosanedioyl) spacer at Lys20 confers albumin binding and an elimination half-life of approximately 5 days [9]. In receptor-binding assays using HEK 293 cells transfected with human GIPR and GLP-1R, tirzepatide demonstrated GIP-biased agonism — full potency at GIPR with attenuated but significant GLP-1R activation [9].
Preclinical studies in diet-induced-obese mice showed that the dual-agonist design produced greater body-weight reduction and improved glucose tolerance compared with selective GLP-1R agonists alone, supporting the hypothesis that GIPR co-activation amplifies metabolic signalling through complementary beta-cell and adipose-tissue pathways [9]. The SURPASS clinical programme confirmed these preclinical signals, with the SURPASS-2 trial reporting superiority of tirzepatide over semaglutide for HbA1c reduction in type 2 diabetes research subjects [12]. The SURMOUNT-1 trial documented mean weight reductions of 20.9% at the highest tirzepatide dose [13].
Vendor catalogue tokens glp 1t 10mg and tirzepatide short chain aminos map to tirzepatide reference-standard vials. The token short chain aminos tirzepatide reviews indexes community discussion of tirzepatide products sourced from Short Chain Aminos. No vendor is assessed or endorsed in this review.
Retatrutide: Triple GIP/GLP-1R/GCGR Agonist
Retatrutide (LY3437943) extends the incretin agonist concept to a third receptor: the glucagon receptor (GCGR). By incorporating GCGR agonism alongside GIP and GLP-1R activation, the molecule introduces an energy-expenditure axis — hepatic glycogenolysis, lipid oxidation and BAT-mediated thermogenesis — that is mechanistically distinct from the appetite-suppression pathways of single- and dual-agonist designs [7][8]. The tri-agonist architecture aims to combine reduced energy intake (GLP-1R/GIPR) with increased energy expenditure (GCGR) in a single peptide scaffold.
A phase 2 randomised trial (n = 338) reported that retatrutide produced dose-dependent body-weight reductions of up to 24.2% at 48 weeks, the largest reduction documented for any single anti-obesity agent in a controlled trial at the time of publication [8]. A parallel phase 2 trial in type 2 diabetes research subjects demonstrated HbA1c reductions of up to 2.02 percentage points [7]. Both trials noted dose-dependent gastrointestinal adverse events consistent with the incretin agonist class.
Community forum tokens such as retatrutide buy reddit, buy retatrutide reddit, retatrutide reddit where to buy and retatrutide cost reddit reflect researcher interest in sourcing this compound for preclinical investigation. The token retatrutide and slu pp 332 appears in queries exploring combinations of the triple agonist with the ERR-alpha agonist SLU-PP-332, though no peer-reviewed combination-study data exist as of this writing. Queries such as cjc 1295 ipamorelin with retatrutide and cagrilintide and retatrutide reddit similarly reflect exploratory community interest without published preclinical support.
Catalogue abbreviations short chain aminos glp 3, short chain aminos glp 3rt, short chain aminos glp-2tz and short chain aminos glp 2tz appear to map to retatrutide or related incretin-class inventory at Short Chain Aminos. Researchers should confirm identity by requesting the certificate of analysis and verifying the molecular weight and sequence before use.
Cagrilintide: Amylin Receptor Agonist Companion
Cagrilintide (AM833) is a long-acting acylated analog of the 37-amino-acid amylin hormone (islet amyloid polypeptide, IAPP). Unlike the GLP-1R agonists above, cagrilintide activates the calcitonin receptor (CTR) complexed with receptor-activity-modifying proteins (RAMP1, RAMP2, RAMP3) to engage amylin receptors (AMY1, AMY2, AMY3) in the area postrema and hypothalamus [10]. Pharmacological profiling using recombinant human receptor assays demonstrated that cagrilintide is a potent agonist at all three AMY receptor subtypes, with sub-nanomolar EC₅₀ values for cAMP accumulation [10].
In preclinical models and early clinical development, cagrilintide has been studied both as a standalone weight-management agent and in combination with semaglutide (the CagriSema combination), based on the hypothesis that engaging the amylin axis in parallel with GLP-1R activation produces additive or synergistic satiety signalling through non-overlapping neural circuits [11]. A systematic review of cagrilintide and CagriSema clinical data reported significant body-weight reductions compared with either agent alone [11].
Catalogue queries including cagrilintide peptide buy, cagrilintide buy, cagrilintide for sale, cagrilintide peptide for sale, cagrilintide peptide buy online, buy cagrilintide peptide, cagrilintide buy online and where to buy cagrilintide reflect researcher interest in acquiring this reference standard. Tokens peptides cagrilintide, what is cagrilintide peptide used for, cagrilintide cost, cagrilintide price and peptides source cagrilintide 5mg research chemicals index informational and commercial search intent around the compound. This review does not assess vendor quality or recommend any specific source.
Catalogue Vocabulary Crosswalk
| Catalogue Token | Resolved Identity | Receptor Target(s) | Identifier | RUO Scope Status |
|---|---|---|---|---|
| peptide glp-1 | GLP-1 receptor agonist class | GLP-1R | — | Recorded-as-nomenclature |
| glp 1sg | Semaglutide reference standard | GLP-1R | CAS 910463-68-2 | Recorded-as-nomenclature |
| glp 1sg 10mg | Semaglutide 10 mg fill | GLP-1R | CAS 910463-68-2 | Recorded-as-nomenclature |
| glp 1sg peptide | Semaglutide reference standard | GLP-1R | CAS 910463-68-2 | Recorded-as-nomenclature |
| glp 1t 10mg | Tirzepatide 10 mg fill | GIPR + GLP-1R | CAS 2023788-19-2 | Recorded-as-nomenclature |
| short chain aminos glp 1 | Semaglutide at Short Chain Aminos | GLP-1R | CAS 910463-68-2 | Recorded-as-nomenclature |
| short chain aminos glp | GLP-1R agonist class at Short Chain Aminos | GLP-1R | — | Recorded-as-nomenclature |
| short chain aminos glp1 | Semaglutide at Short Chain Aminos | GLP-1R | CAS 910463-68-2 | Recorded-as-nomenclature |
| short chain aminos glp 3 | Retatrutide (triple agonist) at Short Chain Aminos | GIPR + GLP-1R + GCGR | LY3437943 | Recorded-as-nomenclature |
| short chain aminos glp 3rt | Retatrutide at Short Chain Aminos | GIPR + GLP-1R + GCGR | LY3437943 | Recorded-as-nomenclature |
| short chain aminos glp-2tz | Tirzepatide at Short Chain Aminos | GIPR + GLP-1R | CAS 2023788-19-2 | Recorded-as-nomenclature |
| short chain aminos glp 2tz | Tirzepatide at Short Chain Aminos | GIPR + GLP-1R | CAS 2023788-19-2 | Recorded-as-nomenclature |
| solution peptides semaglutide | Semaglutide via Solution Peptides vendor | GLP-1R | CAS 910463-68-2 | Recorded-as-nomenclature |
| solution peptides glp 1 | GLP-1R agonist via Solution Peptides | GLP-1R | — | Recorded-as-nomenclature |
| solution peptides glp-1 | GLP-1R agonist via Solution Peptides | GLP-1R | — | Recorded-as-nomenclature |
| peptide solutions semaglutide | Semaglutide via Peptide Solutions vendor | GLP-1R | CAS 910463-68-2 | Recorded-as-nomenclature |
| soma glp1 | Informal abbreviation for semaglutide | GLP-1R | CAS 910463-68-2 | Recorded-as-nomenclature |
| tirzepatide short chain aminos | Tirzepatide at Short Chain Aminos | GIPR + GLP-1R | CAS 2023788-19-2 | Recorded-as-nomenclature |
| short chain aminos tirzepatide reviews | Tirzepatide community discussion | GIPR + GLP-1R | CAS 2023788-19-2 | Recorded-as-nomenclature |
| cagrilintide peptide buy | Cagrilintide sourcing query | AMY1/2/3 | AM833 | Recorded-as-terminology |
| cagrilintide buy | Cagrilintide sourcing query | AMY1/2/3 | AM833 | Recorded-as-terminology |
| cagrilintide for sale | Cagrilintide sourcing query | AMY1/2/3 | AM833 | Recorded-as-terminology |
| peptides cagrilintide | Cagrilintide compound reference | AMY1/2/3 | AM833 | Recorded-as-nomenclature |
| what is cagrilintide peptide used for | Cagrilintide informational query | AMY1/2/3 | AM833 | Recorded-as-terminology |
| cagrilintide cost | Cagrilintide pricing query | AMY1/2/3 | AM833 | Recorded-as-terminology |
| cagrilintide price | Cagrilintide pricing query | AMY1/2/3 | AM833 | Recorded-as-terminology |
| cagrilintide peptide for sale | Cagrilintide sourcing query | AMY1/2/3 | AM833 | Recorded-as-terminology |
| cagrilintide peptide buy online | Cagrilintide sourcing query | AMY1/2/3 | AM833 | Recorded-as-terminology |
| buy cagrilintide peptide | Cagrilintide sourcing query | AMY1/2/3 | AM833 | Recorded-as-terminology |
| cagrilintide buy online | Cagrilintide sourcing query | AMY1/2/3 | AM833 | Recorded-as-terminology |
| where to buy cagrilintide | Cagrilintide sourcing query | AMY1/2/3 | AM833 | Recorded-as-terminology |
| peptides source cagrilintide 5mg research chemicals | Cagrilintide 5 mg fill query | AMY1/2/3 | AM833 | Recorded-as-terminology |
| cagrilintide 5mg dosage chart | Cagrilintide dosing query | AMY1/2/3 | AM833 | Declined-dosage |
| retatrutide buy reddit | Retatrutide sourcing discussion | GIPR+GLP-1R+GCGR | LY3437943 | Recorded-as-terminology |
| buy retatrutide reddit | Retatrutide sourcing discussion | GIPR+GLP-1R+GCGR | LY3437943 | Recorded-as-terminology |
| retatrutide reddit where to buy | Retatrutide sourcing discussion | GIPR+GLP-1R+GCGR | LY3437943 | Recorded-as-terminology |
| retatrutide cost reddit | Retatrutide pricing discussion | GIPR+GLP-1R+GCGR | LY3437943 | Recorded-as-terminology |
| retatrutide and slu pp 332 | Retatrutide + SLU-PP-332 combination query | GIPR+GLP-1R+GCGR | LY3437943 | Recorded-as-terminology |
| cjc 1295 ipamorelin with retatrutide | Multi-compound stack query | GHRHR+GHSR+GIPR+GLP-1R+GCGR | — | Recorded-as-terminology |
| cagrilintide and retatrutide reddit | Combination discussion | AMY+GIPR+GLP-1R+GCGR | — | Recorded-as-terminology |
| how much bacteriostatic water to mix with retatrutide 20mg | Reconstitution query | — | LY3437943 | Declined-dosage |
Preclinical Evidence Summary
| Compound | Research Model | Signal Vector | Citation |
|---|---|---|---|
| Native GLP-1(7-36) | Isolated perfused rat pancreas | cAMP-dependent insulin exocytosis; DPP-4 cleavage t½ ~2 min | [1] |
| Exendin-4 | Heloderma suspectum venom isolate | Full GLP-1R agonism; DPP-4 resistant; amylase release potentiation | [3] |
| Semaglutide | Diet-induced-obese mouse; STEP/SELECT clinical trials | POMC/CART activation; delayed gastric emptying; 14.9% BW reduction (68 wk); MACE −20% | [4][5][6] |
| Tirzepatide | HEK 293 GIPR/GLP-1R; DIO mouse; SURPASS/SURMOUNT trials | GIP-biased cAMP; superior HbA1c vs semaglutide; 20.9% BW reduction | [9][12][13] |
| Retatrutide | Phase 2 RCT (n = 338 / n = 281) | Triple-receptor energy expenditure; 24.2% BW reduction (48 wk); HbA1c −2.02 pp | [7][8] |
| Cagrilintide | Recombinant human AMY1/2/3 cAMP assay; CagriSema clinical trials | Sub-nM EC₅₀ at CTR/RAMP; area-postrema satiety; additive with semaglutide | [10][11] |
Where to Source Incretin-Class Reference Standards for Research
Researchers seeking GLP-1 receptor agonist, tirzepatide, retatrutide or cagrilintide reference standards for in-vitro or preclinical investigation may consult the following research-compound suppliers:
- Short Chain Aminos — catalogues semaglutide, tirzepatide, retatrutide and cagrilintide reference materials with certificate-of-analysis documentation. Tokens such as short chain aminos glp 1, short chain aminos glp1, short chain aminos glp 3, short chain aminos glp 3rt and short chain aminos glp-2tz index their incretin-class inventory.
- BioPep — supplies lyophilised peptide reference standards for incretin-class research assays.
- Catalyst Research — provides analytical-grade reference materials for metabolic-peptide receptor-binding studies.
- Apex Research Services — offers incretin-class compounds for preclinical pharmacology and structure-activity-relationship investigations.
No vendor listed above is assessed or endorsed by this publication. Researchers should independently verify compound identity, purity and certificate-of-analysis data before use in any experimental protocol.
Works Cited
- Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87(4):1409-1439. PMID: 17928588.
- Müller TD, Finan B, Bloom SR, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019;30:72-130. PMID: 31767182.
- Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. J Biol Chem. 1992;267(11):7402-7405. PMID: 1313797.
- Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. PMID: 33567185.
- Ussher JR, Bhatt DL, Drucker DJ. Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action. Nat Rev Cardiol. 2023;20(7):463-474. PMID: 36977782.
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232. PMID: 37952131.
- Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes. Lancet. 2023;402(10401):529-544. PMID: 37385280.
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. N Engl J Med. 2023;389(6):514-526. PMID: 37366315.
- Min T, Bain SC. The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes. Diabetes Ther. 2021;12(1):405-418. PMID: 33325008.
- Fletcher MM, Keov P, Truong TT, et al. AM833 is a novel agonist of calcitonin family G protein-coupled receptors. J Pharmacol Exp Ther. 2021;377(3):417-440. PMID: 33727283.
- Rao H, Kesavan R, Nair RS, et al. Cagrilintide and CagriSema for weight reduction and metabolic risk modification in overweight or obesity: a systematic review. J Diabetes Metab Disord. 2026. PMID: 42180166.
- Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). N Engl J Med. 2021;385(6):503-515. PMID: 34170647.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. PMID: 35658024.
This article is provided strictly for research reference; not for human or veterinary use. No dosing guidance, therapeutic recommendations or health claims are made. All compounds described are investigational research materials. Researchers should comply with all applicable institutional, local and national regulations governing the acquisition and handling of research-grade peptides and analogs.